Article Versions Notes

Hoppe S, Meder L, Gebauer F, Ullrich RT, Zander T, Hillmer AM, Buettner R, Plum P, Puppe J, Malter W, et al. Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus. Cancers. 2022; 14(19):4789. https://doi.org/10.3390/cancers14194789

Hoppe, Sascha, Lydia Meder, Florian Gebauer, Roland T. Ullrich, Thomas Zander, Axel M. Hillmer, Reinhard Buettner, Patrick Plum, Julian Puppe, Wolfram Malter, and et al. 2022. "Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus" Cancers 14, no. 19: 4789. https://doi.org/10.3390/cancers14194789

Hoppe, S., Meder, L., Gebauer, F., Ullrich, R. T., Zander, T., Hillmer, A. M., Buettner, R., Plum, P., Puppe, J., Malter, W., & Quaas, A. (2022). Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus. Cancers, 14(19), 4789. https://doi.org/10.3390/cancers14194789